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ABSTRACT
Alternative splicing is regulated in part by variations
in the relative concentrations of a variety of factors,
including serine/arginine-rich (SR) proteins. The
SR protein SC35 self-regulates its expression
by stimulating unproductive splicing events in
the 30 untranslated region of its own pre-mRNA.
Using various minigene constructs containing the
terminal retained intron and flanking exons, we
identified in the highly conserved last exon a
number of exonic splicing enhancer elements
responding specifically to SC35, and showed an
inverse correlation between affinity of SC35 and
enhancer strength. The enhancer region, which is
included in a long stem loop, also contains
repressor elements, and is recognized by other
RNA-binding proteins, notably hnRNP H protein
and TAR DNA binding protein (TDP-43). Finally,
in vitro and in cellulo experiments indicated that
hnRNP H and TDP-43 antagonize the binding of
SC35 to the terminal exon and specifically repress
the use of SC35 terminal 30 splice site. Our study
provides new information about the molecular
mechanisms of SC35-mediated splicing activation.
It also highlights the existence of a complex
network of self- and cross-regulatory mechanisms
between splicing regulators, which controls their
homeostasis and offers many ways of modulating
their concentration in response to the cellular
environment.
INTRODUCTION
Alternative splicing (AS) occurs during the expression
of most genes and has important functions in many bio-
logical processes. Some of the mechanisms controlling the
alternative choice of splice sites made by cells in response
to various intra or extracellular stimuli are now better
understood, yet many molecular aspects of splicing regu-
lation remain unclear. One key feature of AS regulation is
the existence of a ‘splicing code’ based on the antagonistic
assembly of activator and repressor complexes onto a
variety of cis-acting enhancer and silencer elements,
allowing the activation or repression of alternative splice
sites (1). This relies largely on the relative concentrations
of available splicing activators and repressors. Two major
families of proteins mediate the interactions between
cis-regulatory elements and the spliceosomal machinery:
serine/arginine-rich (SR) proteins (2,3) and hnRNP
proteins (4). AS is also inﬂuenced by its dynamic
coupling to transcription and other mRNA processing
events (5), or by the formation of RNA secondary struc-
tures (6).
A well-known function of AS is to expand the diversity
of the proteome, however a large proportion (about one
third) of AS events create premature stop codons that
are predicted to elicit the nonsense-mediated mRNA
decay (NMD) pathway and to result in the speciﬁc degra-
dation of those mRNAs. Although recent studies do
not support a widespread impact of this phenomenon
(called AS-NMD) on gene expression, it clearly inﬂuences
the expression of some genes by inducing variations in the
production of speciﬁc mRNA isoforms (7). A few years
ago, we and our collaborators described a negative
feedback loop controlling the expression of the SR
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gene is essential and conditional knockout experiments in
mouse or in embryonic ﬁbroblasts have shown that SC35
is involved in the maintenance of genomic stability and in
the control of cell proliferation in thymus and pituitary
gland (9,10). These important biological functions presup-
pose a ﬁnely tuned control of SC35 expression in the cell.
Indeed, high SC35 concentration activates distinct splicing
events within the 30 untranslated region (30 UTR) of its
own pre-mRNA, resulting in the formation of mRNA
isoforms in which the natural stop codon is located far
upstream from the following exon–exon junction (8).
The NMD machinery considers this stop codon as prema-
ture and triggers the degradation of the corresponding
mRNAs (8,11–13).
Other feedback regulation loops have been described
for mammalian SR proteins SRp20, 9G8 and Tra2b1
(14–16), and similar cross-regulatory mechanisms exist
between the highly related TIA1 and TIAR proteins (17)
and between PTB and its paralogs nPTB and ROD1
(18,19). One consequence of those AS events can be the
production of truncated protein isoforms. However, a
series of bioinformatics and biological studies have
recently shown that regulation by evolutionary conserved
AS-NMD is a mode of regulation of gene expression
common to the entire SR family, several hnRNP
proteins and core spliceosomal components (12,20–22).
These ﬁndings suggest the existence of an integrated
network of homeostatic control of the expression
of splicing factors, based on complex AS regulatory mech-
anisms, which are still largely unknown. However,
sequence elements that are ultraconserved (elements
longer than 200bp with 100% identity in human, rat
and mouse genes) or highly conserved (identity over
>100bp) were suggested to participate to those mecha-
nisms (12,21,23).
Here, we studied the molecular mechanisms of
SC35-dependent AS within the 30 UTR of the SC35
pre-mRNA. This model is particularly interesting since
only a few examples of SC35-mediated regulation of
splicing have been studied in detail. We found that
splicing of the terminal intron is activated via multiple
low-aﬃnity SC35-binding sites located within a highly
conserved stem-loop region of the downstream exon.
The same regulatory sequence is also bound by several
proteins, including hnRNP H and TDP-43, which
compete with SC35 binding and antagonize its eﬀect to
repress terminal intron splicing in vitro and in cellulo.
Our results improve our knowledge on the splicing
activator function of SC35 and reveal complex cross-
regulatory mechanisms for the expression of splicing
regulators.
MATERIALS AND METHODS
Plasmids
The previously described SC35-RI plasmid (wt-RI) (8)
was modiﬁed by point mutations to create unique restric-
tion sites within exon 2, in positions +3 (NheI), +38
(AﬂII) and +74 (BamHI) relative to the 30 splice site.
The resulting pre-mRNA was spliced in vitro as the
original SC35-RI.
To create the pSC35-bGlo plasmid, we inserted an
MfeI–MfeI PCR fragment (corresponding to the last
237nt of SC35 terminal intron followed by 172 exonic
nts) into a unique MfeI site located in the middle of
rabbit b-globin intron 2 from the pXJ41 plasmid (24).
The sequence used for enzymatic probing, including
four intronic nts and the ﬁrst 106 nts of SC35 terminal
exon, was cloned into EcoRI and BamHI of the
pGEM-3zf(+) plasmid (Promega). Other constructs are
described in the Supplementary Data.
Proteins
Puriﬁcation of full-length recombinant SC35, ASF/SF2,
hnRNP A1 and of GST-SC35RS and GST-9G8RS
is described by Cavaloc et al. and Gallego et al. (25,26).
Detailed puriﬁcation of His6-hnRNP H RRM1-2,
GST-hnRNP H and GST-TDP-43 is described in
Supplementary Data.
Antibodies
Antibodies raised against a carboxyl-terminal peptide
of SC35 (1SC-4F11) and an amino-terminal peptide
of ASF/SF2 (1D7) were used previously (25). The
antibodies anti-PSF/SFPQ (B92) and anti-PTB/hnRNP I
(SH54) were procured from Abcam and Calbiochem,
respectively. Other antibodies were kindly provided
by D. Auboeuf (anti-p68/DDX5), D. Elliott (anti-
SAFB2), D. Black (anti-hnRNP H), S. Rousseau (anti-
DAZAP1), E. Buratti (anti-TDP-43) and G. Dreyfuss
(anti-hnRNP A1).
RNA aﬃnity chromatography
RNA aﬃnity experiments and MALDI-TOF mass
spectrometry analysis were carried out essentially as
described by Venables et al. (24), with minor modiﬁcations
which are detailed in the Supplementary Data. Several
independent experiments were performed. Proteins for
which the peptide coverage score was signiﬁcantly and
reproducibly higher with RNA I and/or RNA II than
with control RNA in at least two experiments were con-
sidered as ‘speciﬁc’. Speciﬁc binding of some of those
proteins was conﬁrmed by western-blotting.
RNA secondary structure analysis by RNase footprinting
In vitro transcribed 50-end labeled RNA (25fmol) was
pre-incubated in buﬀer D for 10min at 65 C, in the
presence of 2mg tRNA, followed by a slow cooling. The
renatured RNA was then incubated for 30min at 20 Ci n
the absence or in the presence of recombinant SC35 (8, 16
and 32pmol) or hnRNP H RRM1-2 (10, 30 and 50pmol)
in 10ml of buﬀer D. Digestion was carried out for 6min at
20 C in the presence of 0.0005 U of the double-stranded
speciﬁc RNase V1 (Kemotex), 1 U of RNase T1 (Roche)
or 1 U of RNase T2 (Invitrogen), that cleave respectively
after G residues or any nucleotide (but preferentially after
A residues). In the conditions used, both enzymes
preferentially cleave single strands. The production of a
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the reactions were carried out as described by Jacquenet
et al. (27). The cleavage products were fractionated by
electrophoresis on a 10% polyacrylamide-8M urea gel.
The free energie of the 2D structure of the SC35 RNA
was calculated at 37 C and in 1M NaCl with the Mfold
software (28).
RNA-protein UV cross-linking
UV cross-linking assays were carried out in splicing con-
ditions as described by Venables et al. (24), using a ﬁxed
amount of various RNA probes and diﬀerent combina-
tions of puriﬁed recombinant proteins, as detailed in the
ﬁgure legend, and in the presence of 0.1mg Escherichia coli
tRNA. After cross-linking and digestion with RNases A
and T1, complexes were analysed by SDS-PAGE and
autoradiography.
In vitro splicing
In vitro splicing assays were performed and quantiﬁed as
described by Disset et al. (29). When transcripts with dif-
ferent backbones (SC35-RI and Sp1-derived transcripts)
were used in the same experiment and compared one to
another (Figure 6 and Supplementary Figure S5), we
incubated the samples in various conditions of tempera-
ture (between 26 and 30 C) and time (1.5–2h) in order to
obtain equivalent basal splicing eﬃciency.
Transfections and RT–PCR analysis
HeLa cells were transfected in 6-well plates, at 50%
conﬂuency (30% for siRNA experiments), using
lipofectamine 2000 (Invitrogen) according to the manufac-
turer’s instructions. The following amounts of transfected
plasmids were used: 200ng of pSC35-bGlo reporter, 20ng
of pGFP-SC35 (a gift from J. Soret) and 500ng of
pXJ41-hnRNP H or pTT3-FLAG-TDP-43. In all
transfections, 2mg of total DNA was added per well. To
prevent promoter squelching eﬀects, the total amount of
CMV promoter-containing plasmid was adjusted to 1mg
with pGL4-CMV plasmid, derived from pGL4 (Promega).
For caﬀeine treatment, cells were ﬁrst transfected for 24h
with the pSC35-bGlo minigene and then treated for 24h
with 14mM caﬀeine before RNA and protein extraction.
For siRNA treatment, two successive applications of
100nM siRNAs (Eurogentec) were carried out at 24h
interval. Cells were transfected 24h after the second
siRNA treatment with the reporter plasmid and harvested
the next day. Sequences of siRNA were as follows:
TDP-43: 50-GAUGAGAACGAUGAGCCCA-30 or 50-A
GGCUCAUCUUGGCUUUGC-30; hnRNP H1/F: 50-G
UUCUUCUCAGGGUUGGAA-30 or 50-GGAAGAAA
UUGUGCAGUUC-30; Renilla luciferase: 50-GUAGCG
CGGUGUAUUAUAC-30. RNAs were extracted using
TRI Reagent (Sigma-Aldrich), DNAse I-treated (Roche)
and analysed by RT–PCR with the following primers:
forward, 50-ACGGTGCATTGGAACGGACC-30 and
reverse, 50-TAACCATTATAAGCTGCAAT-30. The
intensity of the bands corresponding to the two mRNAs
was quantiﬁed using a Typhoon 8600 Imager and the
ImageQuant software (GE Healthcare Life Sciences)
and corrected to take the relative product size into
account. The ratio inclusion/skipping from three indepen-
dent transfection experiments was normalized using the
control sample of each series as a reference, which gave
a score for inclusion or skipping of the alternative exon.
Proteins were extracted in a buﬀer containing 50mM
Tris–HCl pH 6.8, 20mM EDTA, 5% SDS, sonicated
brieﬂy and analysed by SDS–PAGE and western blotting.
RESULTS
Splicing of terminal SC35 intron requires speciﬁc
downstream exonic sequences
We showed previously that SC35 promotes the inclusion
of an alternative cassette exon and the excision of the
terminal retained intron in the 30 UTR of its own tran-
scripts (8). We analysed the molecular mechanisms
involved in the excision or retention of terminal SC35
intron, ﬁrst using an in vitro system which recapitulates
its SC35-dependent splicing (Figure 1A). As shown by
Sureau et al. (8), the wild-type SC35-RI substrate (for
Retained Intron) was poorly spliced in the presence of
nuclear extract, but splicing was strongly activated upon
the addition of puriﬁed recombinant SC35 (Figure 1C,
lanes 2–3 and 19–20). In contrast, other SR proteins
such as ASF/SF2 (lane 4) or 9G8 (8) did not activate
intron excision. Interestingly, a recombinant SC35
lacking the RS domain had no activator eﬀect and even
slightly reduced splicing compared to the basal level or to
the addition of RS domain-lacking ASF/SF2 (Figure 1C,
lane 21 compared with 19 and 22). This dominant-
negative eﬀect of SC35RS suggested that SC35 plays a
direct role in splicing activation, through interactions
mediated by its RS domain.
The sequence of the entire terminal intron and most of
the following exon is well conserved between human and
mouse SC35 genes. In particular, a highly conserved 132
nt-long sequence, overlapping the 30 splice site (positions
 43 to +89, Figure 1B), is 100% conserved and was sug-
gested to be involved in the control of unproductive
splicing of SC35 transcripts (12). To determine the role
of this region in terminal intron splicing, we ﬁrst
replaced nts 7 to 73 downstream from the 30 splice site
(Figure 1B) by a neutral sequence (Supplementary Data)
and analysed the splicing of this pre-mRNA in vitro.
Both basal and SC35-activated splicing were dramati-
cally inhibited (Figure 1C, compare lanes 5–6 to 2–3),
indicating that this sequence is necessary for splicing.
Mutation of the distal half of the region (44–73) also led
to complete inhibition of basal splicing, but some activa-
tion was observed upon SC35 addition (lanes 13–14),
indicating that this region contains an important part,
but not all the elements required for intron excision.
Further analysis showed that the most active elements
are located within the segment 44–58 (lanes 15–16), and
not in the segment 61–73 (lanes 17–18). Interestingly, sub-
stitution of the proximal half of the 70nt sequence (7–37)
inhibited the natural 30 splice site almost completely, but
weak splicing occurred at a cryptic 30 site (position +43),
due to the improvement of its polypyrimidine tract in the
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stimulated by SC35. We found also that the activatory
elements were distributed all along this proximal region
since the mutation of its two halves (nts 7–23 or 22–37,
lanes 9–12) was without eﬀect on splicing. All results
obtained in nuclear extract were also conﬁrmed in
limiting splicing conditions, using a cytoplasmic S100
fraction complemented with puriﬁed SC35
(Supplementary Figure S1). Altogether, these results sug-
gested the presence of several enhancer elements within
the 60nt-long region downstream from the 30 splice site,
and which contribute to SC35-mediated splicing of the
upstream intron.
The terminal exon contains several SC35-dependent
splicing enhancers
To conﬁrm those results and exclude the possibility that
the neutral sequence inserted in the SC35-RI substrate
contained a strong splicing silencer, we inserted the poten-
tial ESEs into the heterologous Sp1 ‘inverted exon 20
reporter (Figure 2A). Inversion of the second exon of
this adenovirus E1A-derived pre-mRNA resulted in a
dramatic inhibition of splicing in vitro, which can be
restored upon insertion of an ESE (25,29). Indeed,
splicing of control transcripts was nearly or completely
absent, depending on the nuclear extract (Figure 2B,
Figure 1. (A) Schematic organization of the SC35 gene (SFRS2) and of the SC35-RI minigene. The open-reading frame lies within two constitutive
exons, whereas the 30 UTR is alternatively spliced and polyadenylated. The alternative cassette exon and retained intron are represented by black
boxes. (B) Sequence of the region encompassing the 30 splice site of terminal intron and the 50 part of terminal exon. Intronic and exonic nucleotides
are in small and capital letters, respectively. Numbers along the exonic sequence indicate the position relative to the 30 splice site in the wild-type
construct. In the wt* construct, the three newly created restriction sites are underlined. The diﬀerent mutated fragments are in bold. Note that they
do not systematically have the same length as the corresponding wild-type fragment. (C) In vitro splicing of wild-type and mutant SC35-RI
transcripts. Standard splicing assays were carried out in HeLa nuclear extract, supplemented or not by 600–800ng of puriﬁed full-length SC35,
ASF/SF2 or the same proteins lacking the RS domain (RS). The diﬀerent pre-mRNAs are indicated above each panel. The pre-mRNA and splicing
products are symbolized on the side of the gel. Products resulting from the use of an intronic cryptic 50 splice site (intronic position +157) or from
the use of an exonic cryptic 30 splice site are indicated by the mention ‘cryptic’ and by an asterisk, respectively. The activity of SC35 and ASF/SF2
proteins was normalized using a control fushi-tarazu transcript (Supplementary Figure S1A).
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reproducibly observed upon insertion of each of the
three tested overlapping regions of the SC35 terminal
exon [regions I (6–48), II (36–76) and III (70–106), see
sequences in Figures 1B and 2A] in the inverted exon
(lanes 2–4). The strongest activation was obtained with
region II (Figure 2B, lane 3). Next, we progressively
shortened the three regions in order to deﬁne minimal
enhancer motifs. While only a weak splicing activation
was observed with the subfragments of region III,
indicating that no strong enhancers were present in this
region (Supplementary Figure S2), the most eﬃcient of the
numerous fragments that we tested was sequence IIB
(Figure 2B, lane 11, Supplementary Figure S2 and data
not shown), which corresponds to the middle part of
sequence II (nts 46–65, Figure 2A). Then the activation
properties of three sub-fragments of sequence IIB were
tested (IIB-50, M and 30, Figure 2A). The two overlapping
segments 50 and M, corresponding altogether to nts 46–60,
exhibited strong enhancer activity (Figure 2B, lanes 12–
13). Interestingly, this short ESE matched the region
having the highest enhancer activity in the SC35-RI
substrate (nts 44–58, Figure 1). In contrast, the
pre-mRNA containing the IIB-30 segment was barely
spliced (Figure 2B, lane 14), in agreement with data
from Figure 1.
Various RNA sequences bound by SC35 with a strong
aﬃnity have been previously identiﬁed by SELEX,
however most of them, including sequences S-7 and S-94
(Figure 2A), have poor ESE activities (25,30). In addition,
strong SC35-dependent ESEs may bind SC35 with a low
aﬃnity, as does the HIV-1 ESE acting at site A3 (31,32).
Therefore, we wanted to determine whether splicing acti-
vation by SC35 terminal exon ESEs is dependent on SC35
and if this is the case, what is the aﬃnity of SC35 for these
ESEs. To address the ﬁrst question, we compared the
SC35-dependent activation properties of these ESEs to
those of SELEX sequences S-7 and S-94. As expected,
sequence S-7 had no ESE activity in nuclear extract in
the Sp1 reporter (Figure 2B, lane 9). In contrast,
sequences IIB and S-94 had a strong ESE activity (lanes
10–11). The strong eﬀect of sequence S-94 as compared
with our previous data (25) was most likely due to diﬀer-
ent properties of the nuclear extracts used in the two
studies. In fact, when assayed in an S100 fraction, which
is devoid of SR proteins, the S-94-containing transcript
was very weakly activated by puriﬁed SC35 (Figure 2C,
lanes 1–4), showing that the splicing detected in nuclear
extract was mediated by other factors. In contrast, the
Sp1-IIB transcript was eﬃciently spliced upon addition
of recombinant SC35, but not upon addition of ASF/
SF2 (lanes 5–8). Splicing assays in S100 also revealed
that several independent subfragments from sequences I
and II have an SC35-dependent splicing activation
property (data not shown). Altogether, results from
Figures 1 and 2 and from Supplementary Figures S1
and S2 showed that the 50 terminal 60nts of the SC35
terminal exon contain multiple SC35-dependent ESEs
which are required for intron excision.
Finally, we also analysed the SC35-dependent cassette
exon located within the SC35 30 UTR. As for the terminal
exon, we detected several SC35-dependent ESEs within
Figure 2. (A) Schematic view of the heterologous Sp1 ‘inverted exon 2’ splicing substrate. Various sequences, as listed on the right side of the ﬁgure,
were inserted in the middle of the inverted exon 2. Like for sequences from the terminal SC35 exon, the fragments 1, 2 and 3 from the cassette exon
partially overlap one to another (underlined nts). (B) Splicing assays in nuclear extract. Each transcript, harbouring one speciﬁc sequence in exon 2 as
indicated, was incubated and analysed in standard conditions. (C) Splicing assays in cytoplasmic S100 extract. Transcripts, containing either the S-94
or the IIB sequence, were incubated in 8ml S100 supplemented with 3ml of a 20–40% ammonium sulphate-precipitated fraction from HeLa nuclear
extract and with 400ng of recombinant SC35 or ASF/SF2 protein. As previously shown (25,30), eﬃcient and speciﬁc splicing activation in the S100
fraction could only be observed in the presence of this 20–40% fraction, which does not contain SR proteins.
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another highly conserved element (12) (Figure 2B, lanes
5–7 and data not shown). However, we did not character-
ize these sequences any further.
SC35 and several hnRNP proteins bind to exonic
regions I and II
To address the question of SC35 binding to the diﬀerent
ESEs from the terminal SC35 exon, we ﬁrst performed
electrophoretic mobility shift assays (EMSA). Figure 3A
shows that the RNA-recognition motif (RRM) of SC35,
but not that of 9G8, interacted with RNA probe IIB
(lanes 1–5). However, the binding aﬃnity was lower
than with SELEX sequences S-94 and more particularly
S-7 (at least six times lower) (lanes 6–9 and 11–14).
Interestingly, even though those three RNA sequences
present some homology (Figure 3B), their RNA-protein
aﬃnity and their ESE potential seemed to be inversely
correlated: the lower the aﬃnity of SC35 for a given
sequence, the higher the ESE activity of this sequence,
and vice versa.
One possible explanation could be that eﬃcient SC35-
mediated splicing requires not only binding of SC35 to an
ESE, but also the binding of a cofactor. This would
explain why a high aﬃnity SC35 sequence isolated by
SELEX is not suﬃcient per se to promote splicing.
To identify potential SC35 coactivator(s), we performed
parallel RNA aﬃnity chromatography experiments with
exonic sequences I and II that included the most proximal
ESE and the ESE IIB, respectively. The experiment was
carried out in splicing conditions to favour the formation
of splicing-competent complexes. As negative controls, we
used exonic sequence III since it was not required for
terminal intron splicing (data not shown), and sequence
S-7 as we postulated that coactivator(s) should not bind to
this RNA. The proteins remaining bound to RNA after
low-salt washes were analysed by silver staining. We
observed a complex pattern of proteins and a high
non-speciﬁc background (proteins bound onto the three
RNAs), but bands speciﬁc for sequences I or II were
detected (Supplementary Figure S3). In particular, a
larger number of proteins interacted with RNA I than
with other sequences. Proteins contained in the bands
which were more speciﬁc to sequences I and II were
identiﬁed by mass spectrometry. We found many
hnRNP proteins and other RNA-binding proteins
known to be involved in pre-mRNA processing or RNA
stability (Supplementary Figure S3).
We then analysed the binding of some of those proteins
by western blotting. This conﬁrmed that hnRNP H,
hnRNP A1 and DAZAP1 interacted only or preferentially
with SC35 sequence I (Figure 3C, compare lane 1 to other
lanes). Other proteins like TDP-43 and the RNA helicase
p68/DDX5 bound sequences I and II equally well and
speciﬁcally (lanes 1–2). Consistent with the presence of
C/U-rich stretches within sequence III, which is a good
target for the splicing regulator PTB/hnRNP I, this
factor was found strongly associated to this sequence and
weakly to others. In contrast, PSF/SFPQ bound to each
of the tested RNAs and to uncoated beads. Finally, in
agreement with results of Figure 3A, we observed a weak
but signiﬁcant binding of SC35 on sequences I and II (lanes
1–2), whereas it interacted eﬃciently with RNA S-7 (lane
4). The weak interaction of SC35 with sequences I and II
was also conﬁrmed by UV cross-linking of RNA-protein
complexes formed in HeLa nuclear extract (Supplementary
Figure S4). Other SR proteins, like ASF/SF2, or other
splicing factors such as SAFB2, did not bind signiﬁcantly
to any of the exonic sequences (Figure 3C and data not
shown). We concluded that SC35 interacts speciﬁcally with
several low-aﬃnity elements within region I/II of terminal
exon, a region which is also recognized speciﬁcally (directly
or indirectly) by several RNA-binding proteins.
Footprinting assays conﬁrm the presence of several
SC35 binding sites in the SC35 terminal exon
Since the secondary structure of pre-mRNAs often plays a
role in splicing regulation, we analysed the structure of the
Figure 3. (A) Electrophoretic mobility shift assay. The complexes
formed between the RNA probes (10fmol) and GST-SC35RS (10,
20 and 30ng) or GST-9G8RS (30ng) were resolved by native gel
electrophoresis to separate the protein-RNA complexes (bound) from
the free RNA (free). (B) Sequence homology between the sequence
IIB from the SC35 terminal exon (nts 46–65) and SC35 high aﬃnity
sequences S-7 and S-94 sequences. (C) Western-blot of an RNA aﬃnity
experiment. Equivalent amounts of proteins retained on the diﬀerent
immobilized RNA probes (lanes 1 to 4), or on naked beads (lane 5)
were analysed using various antibodies. The input corresponded to
1.5ml of HeLa nuclear extract. nd: not determined.
1358 Nucleic Acids Research, 2010, Vol.38, No. 4enhancer/silencer region by enzymatic probing, using an
RNA fragment that included the last four intronic nts and
the ﬁrst 106nts of SC35 terminal exon. Enzymatic diges-
tion of naked RNA with RNAse V1, T1 or T2 (Figure 4A,
lanes 2, 7, 11 and 15) allowed us to build a secondary
structure model for the region  4 to 81, which basically
consisted in a long stem-loop structure with several small
internal loops (Figure 4C, left side). Interestingly, unlike
the 50 half of the stem-loop, the segment 55–80 showed no
detectable sensitivity to the diﬀerent enzymes, suggesting
that it may be buried within the overall 3D structure.
Enzymatic footprintings were then performed using
increasing concentrations of recombinant SC35 protein.
At 0.8mM SC35, we detected a weak protection of the
Figure 4. (A) The RNA was incubated in the absence ( ) or in the presence of diﬀerent concentrations of SC35 recombinant protein, as indicated
above each lane. Digestions with RNases V1 (lanes 7–10), T1 (lanes 11–14) or T2 (lanes 15–18) were carried out as described in the ‘Materials and
methods’ section. As a control, undigested RNA was fractionated in parallel (lanes 3–6). Lanes OH  and T1 den, corresponding respectively to
alkaline hydrolysis and RNase T1 digestion in denaturing conditions, were used for localization of the cleavage sites. Nucleotides with decreased
sensitivity to RNases in the presence of SC35 protein are indicated on the right. (B) The same experiment as in A was done using the hnRNP H
RRM1-2 recombinant protein. (C) Secondary structure model proposed for SC35 terminal exon. The model was proposed based on thermodynamic
considerations and on the results of enzymatic digestions shown in A and B. V1, T1 and T2 RNase cleavages are represented by arrows surmounted
by squares, dots and triangles, respectively. Red, orange and green symbols indicate a strong, medium or low cleavage, respectively. The residues
protected by SC35 (1.6mM) or hnRNP H RRM1-2 (3.2mM), or having a modiﬁed sensitivity in the presence of hnRNP H RRM1-2 (3.2mM) are
circled in purple or indicated by a blue or a pink star, respectively (the line thickness is proportional to the protection strength).
Nucleic Acids Research,2010, Vol.38, No. 4 1359terminal loop and of residue G11 (Figure 4A, lanes 12 and
16 compared to lanes 11 and 15, respectively; results are
summarized in Figure 4C). However, at 1.6mM, most of
the segments which were highly sensitive to RNases T1/T2
in the naked RNA (terminal loop and segment 4–11) were
partially protected (lanes 13 and 17) and some of the
RNase V1 cleavages disappeared (lane 9 compared with
lane 7). This indicated an extended binding of SC35 to this
region at this protein concentration, conﬁrming the
presence of several SC35 binding sites. When increasing
the SC35 concentration to 3.2mM, the RNA was entirely
wrapped by the protein since no RNase cleavage was
detected (Figure 4A, lanes 10, 14 and 18). Interestingly,
initial SC35 binding seemed to occur in the apical loop,
which overlaps the 50 part of sequence IIB, and around
position G24 in region I.
Splicing repressors bind exonic sequence I and II
To conﬁrm the binding of trans-acting regulators to the
RNA elements located within sequences I and II, we per-
formed competition experiments using these RNAs as
competitors and various in vitro splicing substrates
(Supplementary Figure S5). As expected, these experi-
ments highlighted the binding of splicing activator(s) to
terminal exon sequences but surprisingly, they also
revealed that region I, and to a lesser extent region II,
are bound by at least one speciﬁc splicing repressor that
speciﬁcally antagonizes the activity of the ESE IIB.
Interestingly, the stronger repressor activity of sequence
I correlated with the larger number of proteins interacting
with this region (Figure 3 and Supplementary Figure S3).
The identiﬁcation of splicing inhibitor(s) among the
proteins found associated to the 50 part of the terminal
exon would have been laborious due to their elevated
number. Therefore, prior to testing potential candidates,
we fractionated a HeLa nuclear extract through diﬀerent
chromatographic steps and tested the resulting fractions
for their sequence-speciﬁc repressor activity in vitro using
the Sp1-IIB substrate (Supplementary Figure S6A and B).
The most repressive fraction that we obtained was
enriched in TDP-43 and hnRNP H proteins, but con-
tained no or weak amounts of the other region
I-interacting factors such as hnRNP A1, DAZAP1 or
p68/DDX5 (Supplementary Figure S6C). We therefore
focused our attention on those two splicing factors.
TDP-43 and hnRNP H compete with SC35 for binding
to the terminal exon sequences
In order to determine whether the binding of hnRNP H
and TDP-43 proteins to the enhancer/silencer region of
terminal exon could interfere with SC35 binding, we
carried out UV cross-linking experiments using various
concentrations of recombinant proteins, in conditions
(low amount of S100 extract and of competitor tRNA)
which allowed a good detection of the interactions. As
shown in Figure 5, recombinant SC35 protein (added to
a S100 extract) cross-linked signiﬁcantly to sequences I
and IIB (lanes 1–2 and 9–10, respectively). Interestingly,
the addition of increasing amounts of recombinant
hnRNP H (lanes 3–4 and 11–12) or TDP-43 (lanes 5–6
and 13–14) proteins reduced the cross-linking of SC35
to both sequences, indicating that those two proteins
directly competed with SC35 for overlapping or very
nearby binding sites. This competition was probably
facilitated by the weak aﬃnity of SC35 for these regula-
tory sequences (Figure 3). Indeed, neither the binding of
hnRNP H to sequences I and IIB, nor that of TDP-43,
was signiﬁcantly impaired by the addition of recombinant
SC35 (compare lanes 4 and 7, 6 and 8, 12 and 15, 14 and
16). In fact, only a 3-times higher SC35 concentration
could slightly reduce hnRNP H binding, but not
TDP-43 binding (data not shown). Finally, although
hnRNP H (but not TDP-43) also cross-linked with
sequence S-7, it could not inhibit the strong interaction
between SC35 and this sequence (lanes 17–20), either
because the aﬃnity of SC35 for this sequence is too
strong, or because the binding sites of both proteins do
not overlap. A similar result was observed with an
unrelated control sequence, although the interactions of
SC35 and hnRNP H with this sequence were very weak
(lanes 21–24).
We next carried out footprinting assays with the
hnRNP H N-terminal RRMs 1 and 2, responsible for
speciﬁc RNA recognition (33) to identify the binding
sites for this protein. The results of these experiments
(Figures 4B and 4C) revealed an increased reactivity
Figure 5. UV cross-linking assays. RNA probes I (lanes 1–8), IIB (lanes 9–16), S-7 (lanes 17–20) or control C (lanes 21–24) (see sequences in Figure
2A) were incubated with 2ml of cytoplasmic extract S100 alone (lanes 1, 9, 17 and 21) or complemented with the following concentrations of puriﬁed
recombinant proteins, as indicated above the ﬁgure: 400nM FLAG-SC35, 250 and 500nM hnRNP H, 175 and 350nM TDP-43 (or the maximal
amount of either protein added in lanes 7–8 and 15–16). Both recombinant hnRNP H and TDP-43 proteins migrated as double bands, which resulted
either from premature termination of translation or from partial proteolytic digestion during the puriﬁcation procedure (data not shown). The
protein marked by an asterisk, which cross-linked only to the S-7 RNA in the S100 extract (lane 17), might correspond to residual amount of
endogenous SC35 that escaped the nuclei during the preparation of the extract.
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overlaps sequence IIB, and a weak increase of the reactiv-
ity of residues 79 and 81. Such variations suggest that
hnRNP H induced a modiﬁcation of the RNA structure,
in contrast to what we observed with SC35. Most
importantly, however, we observed also a strong protec-
tion of the segment 40–45, which overlaps regions I and II
and corresponds to one of the major SC35 binding sites
(Figure 4A and C).
Altogether, results of Figures 4 and 5 indicated that
hnRNP H and TDP-43, two proteins which are enriched
in a fraction that represses SC35-mediated splicing, have
binding sites which overlap those of SC35 within the
terminal exon, and that both proteins eﬃciently and spe-
ciﬁcally compete the low-aﬃnity binding of SC35 to that
region.
TDP-43 and hnRNP H inhibit splicing of SC35
terminal intron in vitro
We next addressed directly the potential repressive eﬀect
of hnRNP H and TDP-43 on SC35 terminal intron
splicing, using in vitro splicing assays. As shown in
Figure 6A, recombinant TDP-43 and hnRNP H proteins
both inhibited moderately the splicing of the SC35-RI
transcript (lanes 3 and 4 compared to lane 2), but they
had a cooperative eﬀect when added together (lane 5),
inhibiting splicing by over 60%. Despite its complete
absence in our enriched repressor fraction (Supplementary
Figure S6C), hnRNP A1 also inhibited strongly the
splicing of this pre-mRNA (lane 6). However, this eﬀect
was not dependent on the presence of the terminal SC35
exon since hnRNP A1 inhibited weakly and equally the
chimeric Sp1-ter-ex and the control Sp1-wt transcripts
(Figure 6B, lanes 6 and 11 compared with lanes 2 and
8). In contrast, TDP-43 and hnRNP H inhibited speciﬁ-
cally Sp1-ter-ex splicing (40 and 35% inhibition, respec-
tively) (lanes 3–4 and 9–10). Similarly, the Sp1 transcript
containing the sequence IIB, but not an ASF/SF2-speciﬁc
sequence, was also inhibited by TDP43 and hnRNP H
(Figure 6B, lanes 13–16 and lanes 19–21), while only a
weak inhibition was observed with hnRNP A1 (lanes 17
and 22). We concluded that TDP-43 and hnRNP H
inhibit terminal SC35 intron splicing in vitro in a
sequence-speciﬁc manner.
In this last experiment using the Sp1-IIB transcript, the
level of inhibition by TDP-43 and hnRNP H (about 25%)
was lower than with the Sp1-ter-ex transcript, most
likely because less potential binding sites were available,
in agreement with the results of footprinting experiments
using the RNA-binding domains of hnRNP H (Figure 4).
Finally, it is also interesting to note that unlike for SC35-
RI transcripts, we did not observe any cooperative eﬀect
of TDP-43 and hnRNP H with Sp1-derived substrates
(Figure 6B, lanes 3–5 and 14–16), suggesting that
Figure 6. (A) Repression of SC35-RI pre-mRNA splicing by hnRNP proteins. The transcript is schematized on top of the ﬁgure. Splicing was
carried out in standard conditions in the absence or presence of 300, 320 or 480ng of puriﬁed recombinant GST-hnRNP H, hnRNP A1 or
GST-TDP-43, respectively, or half of those amounts when two proteins were added together. Splicing eﬃciencies were calculated as in
Supplementary Figure S5 and are indicated under each lane. (B) Splicing of Sp1-derived pre-mRNA in the presence of recombinant hnRNP
proteins. The diﬀerent transcripts are schematized on top of each panel. The common backbone derived from the wild-type Sp1 pre-mRNA (top
right panel) is represented by grey boxes. The white box in the chimeric Sp1-ter-ex transcript symbolizes the terminal exon from the SC35-RI
transcript, while the minimal SC35 IIB sequence and the control ASF/SF2-speciﬁc sequence are represented by a small white (Sp1-IIB) or black
(Sp1-ASF) box, respectively. The experiment was carried out as in A.
Nucleic Acids Research,2010, Vol.38, No. 4 1361inhibition of terminal intron splicing is more complex in
the original sequence environment and may involve other
binding sites within the regulated intron or in the
upstream exon.
TDP-43 and hnRNP H repress the terminal SC35 30
splice site in cellulo
To conﬁrm our results in a cellular context, we designed a
minigene that recapitulated SC35-dependent activation of
terminal SC35 30 splice site. We introduced a fragment of
the SC35 gene, spanning the 30 part of terminal intron and
the regulatory exonic region, into the b-globin intron of a
CMV promoter-driven plasmid. The resulting minigene
(pSC35-bGlo, Figure 7A) had two alternative 30 splice
sites and its splicing in HeLa cells, as analysed by
RT-PCR, resulted in the formation of two main
products, corresponding to mRNAs spliced at the
b-globin (lower band) or SC35 (upper band) 30 splice
site (Figure 7B, lane 1). As expected, co-transfection of
GFP-tagged SC35 stimulated the use of the SC35 30
splice site by over 3-fold (lane 2). A similar result was
obtained when endogenous SC35 expression was increased
upon treatment of cells with caﬀeine (34) (Figure 7B, lanes
9–10, Figure 7C). In contrast, targeting the SC35 gene
with small-interfering RNAs (siRNA), even though the
global level of SC35 protein was reduced only by about
a half, resulted in a strong inhibition of the SC35 30 splice
site (Supplementary Figure S7). These results indicated
that our substrate responded speciﬁcally to changes in
endogenous SC35 levels.
We next tested the eﬀect of hnRNP H or TDP-43
on the minigene. Unlike what we observed in vitro,
over-expression of hnRNP H did not repress the use of
the SC35 30 splice site, and even had a moderate opposite
eﬀect (Figure 7B, lane 3). However, silencing of hnRNP H
expression led to an increase in ‘SC35’ mRNA relative to
b-globin mRNA (Figure 7E and 7D, compare lanes 1 and
3), indicating that hnRNP H has a direct or an indirect
negative eﬀect on the SC35 30 splice site. We obtained the
same result with two diﬀerent siRNAs, targeting both
hnRNP H and F, conﬁrming that splicing modulation
was due to the speciﬁc depletion of these two proteins.
Similarly, over-expression and depletion of TDP-43
did not provide fully consistent results: nearly com-
plete silencing of TDP-43 gene using two distinct siRNA
(Figure 7E and data not shown) had no signiﬁcant eﬀect
on splicing (Figure 7D, lane 4). Yet, over-expression of
TDP-43 led to a dramatic inhibition of the SC35 30
splice site (Figure 7B, lane 4). Interestingly, TDP-43
overcame the GFP-SC35-mediated activation of splicing
Figure 7. (A) Schematic structure of the pSC35-bGlo minigene. A fragment of the SC35 gene including the 30 part of the retained terminal intron
(thick black line) and the 50 part of the terminal exon (white box) was inserted in the rabbit b-globin intron 2, creating a reporter with alternative 30
splice sites (splicing is represented by broken ﬁlled lines). When the SC35 30 splice site was used, a cryptic 50 splice site located downstream from the
insert, within the 30 part of the b-globin intron, was systematically activated (broken dotted line), creating an ‘SC35’ alternative exon. (B) and
(C) RNA and protein analysis after transfection of HeLa cells. Cells were cotransfected with the pSC35-bGlo minigene and plasmids carrying various
cDNAs as indicated above the gels. RNA and protein samples were extracted and analysed respectively by RT-PCR (B) or western blotting (C) with
speciﬁc antibodies, as indicated. Anti-GFP was used to monitor the amount of GFP-SC35 protein, which could not be detected using anti-SC35
antibodies due to its low level of expression. AS gave rise to two major mRNA products depending on the use of the b-globin (lower band) or SC35
(upper band) 30 splice site. (D) and (E) RNA and protein analysis after siRNA-mediated knockdown of hnRNP H/F or TDP-43. RT-PCR analysis
and quantiﬁcation of mRNA products (D) was as in panel B. Eﬃciency of silencing and endogenous level of SC35 protein were monitored by
western-blotting (E) as in panel C.
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7–8 compared to lane 6, and Figure 7C), indicating a com-
petition between the two proteins for regulating the SC35
30 splice site. No further inhibition was observed when we
co-expressed TDP-43 and hnRNP H (data not shown).
Importantly, the level of endogenous SC35 remained
constant in all experiments (Figure 7C and E), indicating
that the eﬀects were primarily due to the over-expression/
depletion of the corresponding proteins, although we
could not exclude the contribution of uncharacterized sec-
ondary eﬀects. Altogether, our results conﬁrmed our in
vitro data and showed that hnRNP H and TDP-43 both
repress the SC35 30 splice site in cellulo in a manner antag-
onistic to SC35.
DISCUSSION
Splicing activation by SC35
In a previous report, we showed that SC35 regulates its
own expression by promoting speciﬁc AS reactions within
the 30 UTR of its pre-mRNA, resulting mostly in the for-
mation of 1.6 and 1.7kb mRNA isoforms in which the
terminal intron has been spliced out (8). The instability
of these isoforms is due to the activation of NMD
(8,11–13), conﬁrming the existence of a negative
feedback loop for SC35. In the present study, we identiﬁed
a 60-nt sequence within the terminal SC35 exon, which is
required for SC35-mediated splicing of the retained
intron. The most active elements are located within
overlapping segments IIB-50 and IIB-M of the 20-nt
sequence IIB (Figure 2 and Supplementary Figure S2).
Systematic mutagenesis of this sequence suggested that
the core motif GUUGCAGU is essential for ESE
activity, but that ﬂanking sequences are also important
(Supplementary Figure S2). We also found some highly
conserved regulatory elements within the 30 part of the
SC35 cassette exon, which present some homology with
the ESE IIB (data not shown). A comparison of the IIB
element to other SC35-speciﬁc ESEs (Supplementary
Table S1) showed a large variety of motifs, and no
unique consensus sequence could be deﬁned. Some
motifs found in the ESE IIB, the SELEX S-94 sequence
(see an alignment of these 2 sequences in Figure 3B) and
the b-globin gene (35) are similarly rich in pyrimidines. In
contrast, other ESEs are more purine-rich (Supplementary
Table S1), whereas a C-rich consensus sequence was
identiﬁed by functional selection of SC35-responsive
ESEs (36). As the ESEﬁnder program was based on this
last consensus sequence (37), it only predicted low-score
SC35 motifs within the 60-nt ESE of SC35 terminal exon
(Supplementary Figure S8).
Unlike high-aﬃnity SC35 SELEX sequences which have
poor ESE activity, the potent ESE IIB and other
SC35-binding sites within the 60-nt ESE were recognized
only weakly by the SC35 RRM or by endogenous SC35
within a nuclear extract (Figure 3). Several hypotheses can
be raised to explain this discrepancy. It is possible that a
strong interaction between the SC35 RRM and RNA does
not confer enough mobility to the protein to develop other
interactions that are necessary for splicing activation.
Alternatively, eﬃcient activation by SC35 might require
the binding of a cofactor(s) near low-aﬃnity SC35
binding sites. This may be required to assemble an
active SC35 enhancer complex, similarly to the assembly
of enhancer complexes to Drosophila doublesex
purine-rich elements (38). Sequences selected by SELEX
using puriﬁed SC35 would not contain the cofactor
binding site and would therefore be inactive in splicing
assays. The factors which we found to bind speciﬁcally
to the SC35-responsive ESE are potential cofactors.
However, the over-expression or knockdown of several
candidates (such as DAZAP1 and p68/DDX5) did not
aﬀect SC35-dependent use of terminal 30 splice site in
cellulo (data not shown).
Interestingly, our footprinting experiments indicated
that the most active SC35-responsive motif (IIB)
overlaps with the most accessible SC35-binding site in a
14-nt single-stranded loop that caps a long stem-loop
region (Figure 4). However, in agreement with results
from Figure 3, which suggested the existence of several
SC35 binding sites in the regulatory region, it became
entirely protected from enzymatic degradation at higher
SC35 concentration (Figure 4). It is possible that the
apical loop represents a primary binding site for the
protein, which would promote the binding of SC35 mole-
cules to other sites along the 60-nt region. Similar mech-
anisms have been described for hnRNP A1 or SC35
binding on HIV-1 transcripts (31,32). Our footprinting
experiments suggest that hnRNP H may modify the
RNA structure upon binding and might alter the
binding and/or the eﬀect of other splicing regulators.
The fact that p68 binds to the regulatory region also
raised the hypothesis that this RNA helicase may have a
similar eﬀect. Remodeling of an RNA structure by p68
was recently proposed to regulate the inclusion of H-Ras
exon IDX by decreasing the binding of hnRNP H (39).
However, our experiments did not support a direct eﬀect
of p68 on the splicing of the pSC35-bGlo minigene
in cellulo (data not shown).
Repression by TDP-43 and hnRNP H
About a dozen of RNA-binding proteins bound speciﬁ-
cally to the regulatory region downstream from the
retained SC35 intron. At least two of them, TDP-43 and
hnRNP H, but not hnRNP A1, repressed splicing in a
sequence-speciﬁc manner in vitro and in cellulo. Both
TDP-43 and hnRNP H, which respectively recognize
UG repeats and GGG-containing motifs, are well-known
AS regulators (4,40). We could not carry out footprinting
analysis using the full-length recombinant proteins, due to
their poor solubility. Interestingly however, the 60-nt reg-
ulatory region of the SC35 terminal exon contains a few
potential TDP-43 binding sites, whereas it does not
contain any G triplet. In fact, the major binding site for
the hnRNP H RNA binding domains is a UAAGG motif
located in the apical stem-loop, which overlaps an
SC35-binding site and which likely explains the direct
competition that we observed between the two antagonis-
tic factors (Figure 5). However, only TDP-43, but not
hnRNP H, competed the eﬀect of SC35 and repressed
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dependent manner (Figure 7). The absence of eﬀect of
over-expressed hnRNP H could be due to the high
endogenous level of hnRNP H in HeLa cells, which is
consistent with the basal repressed state of this 30 splice
site and with its stimulation upon hnRNP H knock-down.
HnRNP F, which was also targeted in our siRNA exper-
iments, may also be a repressor of the 30 splice site, since
this protein has similar functions to hnRNP H. However,
it is unlikely to be the main repressor for two reasons:
hnRNP H eﬃciently inhibited splicing in vitro in a
sequence-speciﬁc manner (Figure 6), and hnRNP F was
not enriched in the repressor fraction that inhibited
splicing of the Sp1-IIB substrate in vitro (Supplementary
Figure S6C).
TDP-43 speciﬁcally repressed splicing of SC35 30 splice
site both in vitro and in cellulo, but its knock-down did not
have any eﬀect on splicing. The most likely explanation is
that the repression could result from a combined action of
several factors: hnRNP H could play a key role in trigger-
ing splicing inhibition by competing directly the binding of
SC35, while TDP-43 may only promote further repression
when its expression is increased, possibly by preventing
the expansion of SC35 binding along the enhancer
region. It is also possible that other proteins among
those that we identiﬁed are involved in splicing repression
in vivo. The AU-rich binding proteins AUF1/hnRNP D
and KSRP/FBP2 are frequently found associated to 30
UTRs and might be involved in other aspects of mRNA
metabolism such as stability or transport. However,
several of the factors identiﬁed can modulate AS (4,41),
and eﬃcient inhibition could result from the assembly of a
multi-protein complex containing a combination of those
factors.
Consequences for the regulation of SC35
expression in vivo
Our cross-linking and titration experiments (Figure 5 and
Supplementary Figure S4) indicate that repressors have a
stronger aﬃnity than SC35 for the regulatory region. This
suggests that SC35 could activate splicing only when a
thresholdconcentrationisreachedtoovercomethebinding
of repressors and to occupy most binding sites along the
60-nt region. This model is functionally sound since it
would provide a ﬁnely tuned negative control of SC35
expression: splicing of terminal intron and NMD-
mediated degradation of mRNAs would only occur when
SC35 concentration becomes too elevated. Although the
proper regulation of AS in cells likely tolerates some vari-
ations in the concentration of SC35, such a safeguard
mechanism might be essential since SC35 plays important
roles in the control of cell proliferation (9,10).
In fact, the treatment of cultured HeLa or nasal epithe-
lial cells with NMD inhibitors revealed the presence of
signiﬁcant amounts of SC35 1.6/1.7 kb mRNA isoforms,
which result from splicing activation by SC35 (8,11–13).
This indicates that terminal intron can be spliced out in
standard cell growing conditions. Similarly, transfection
of HeLa cells with our minigene also showed a signiﬁcant
basal use of terminal SC35 30 splice site (Figure 7).
A prediction from those results is that SC35 concentration
should not increase strongly when SC35 gene transcrip-
tion is increased. Yet, a 3–4-fold increase of SC35 concen-
tration has been reported in several well-deﬁned biological
conditions, in apparent contradiction with the concept of
feedback regulatory loop. For example, caﬀeine treatment
of various cells, including HeLa cells, induced an increase
of SC35 protein level (34) (Figure 7), through a mecha-
nism which is not well understood. However, the same
caﬀeine concentration can also inhibit NMD (42), so it
cannot be ruled out that the 1.6/1.7kb mRNA isoforms
were stabilized, increasing the overall concentration of
SC35 mRNA and protein.
Another recent study showed that over-expression of
the transcription factor E2F1 directly stimulated the tran-
scription of the SC35 gene and the synthesis of SC35
protein in human lung carcinoma cells (43). The basal
SC35 concentration seemed weaker in this cell line than
in mouse embryonic ﬁbroblasts, suggesting that SC35 was
present in suboptimal amounts and that its increased con-
centration was tolerated as being below the critical thresh-
old level that triggers the feedback loop. Moreover, E2F1
stimulates cell cycle progression, and a recent study
reported that proliferating cells tend to express mRNAs
with shorter 30 UTR regions compared to nonactivated
cells (44). E2F1 may induce the synthesis of speciﬁc
SC35 transcripts using the proximal poly-A site, which
is located in the terminal intron (Figure 1), leading to
the accumulation of the 1.3kb, NMD-insensitive mRNA
isoform and to an increase in SC35 protein synthesis.
The presence of important splicing regulatory elements
in the 30 UTR of the SC35 gene, that we demonstrated for
the ﬁrst time in this study, gives one explanation for the
extreme conservation of this region in vertebrates (the reg-
ulatory 60-nt region is nearly 100% conserved from human
to xenopus). Even though this extreme conservation could
also reﬂect, for example, the presence of binding sites for
microRNAs or for factors regulating the stability of the
mRNAs, our ﬁndings support the hypothesis that was
raised following the identiﬁcation of similar highly
conserved or ultraconserved elements associated to
AS-NMD events in the pre-mRNAs of many splicing
factors (12,21,23). One can anticipate that the expression
of a large proportion of splicing regulators is controlled in
similar ways as that of SC35, through an intricate interplay
of self- and cross-regulatory mechanisms. This may
provide the cells with a way to maintain the homeostasis
of those factors to ensure that splicing does not escape
control. It also oﬀers multiple ways of modifying
transiently the relative expression of speciﬁc factors,
which is one of the keys for controlling AS choices.
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